Yorvipath Injection, Solution
Product Images NDC 73362-102

Product Visual Gallery

This gallery contains 57 technical images submitted to the FDA as part of the official labeling for Yorvipath (NDC 73362-102). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascendis Pharma, Endocrinology, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Yorvipath 01)

An instructional flowchart for Yorvipath dosing adjustments based on duration of treatment. It advises increasing calcium or vitamin D supplements or continuing the same Yorvipath dose if less than 7 days since starting or changing dose, and increasing Yorvipath dose by 3 mcg with consistent calcium and vitamin D supplementation if 7 days or more have passed.*

FDA Label Image

Figure 1 (Yorvipath 02)

A flowchart depicting dosing adjustment guidelines for Yorvipath (palopegteriparatide) injection. It outlines decisions based on treatment duration, vitamin D and calcium supplement intake, and calcium supplement levels, leading to continuing the same dose, decreasing supplements, or increasing Yorvipath dose by 3 mcg accordingly.*

FDA Label Image

Figure 1 (Yorvipath 03)

A decision flowchart illustrating dosage adjustments for Yorvipath (palopegteriparatide) related to active vitamin D and calcium supplement use. It guides whether to decrease or discontinue active vitamin D, adjust Yorvipath dose by 3 mcg, or modify calcium supplement intake based on specific conditions and supplement amounts.*

FDA Label Image

Figure 2 (Yorvipath 04)

Chemical structure diagram of Palopegteriparatide, showing mPEG succinimide, TransCon Linker, and PTH(1-34) peptide sequence. The peptide sequence is depicted as connected amino acid residues from Ser to Phe, illustrating the molecule's components and linkages.*

FDA Label Image

Figure 3 (Yorvipath 05)

A line graph showing the mean albumin-corrected serum calcium levels (mg/dL) over time (hours) from 0 to 24. The graph includes error bars indicating standard error around each time point's mean value.*

FDA Label Image

Figure 4 (Yorvipath 06)

A line graph depicting the mean steady state PTH levels (pg/mL) over time in hours from 0 to 24. The graph shows data points at intervals including 0, 4, 8, 12, 16, 20, and 24 hours, with error bars indicating standard error. The PTH levels rise slightly around 4 hours and then gradually decline toward 24 hours.*

FDA Label Image

Image (Yorvipath 07)

Instructions for use for Yorvipath (palopegteriparatide) injection, for subcutaneous use, including dosing information for 6, 9, or 12 mcg doses. The image shows a prefilled pen labeled Yorvipath 168 mcg/0.56 mL (300 mcg/mL) for injection, intended for specified dose administration.*

FDA Label Image

Image (Yorvipath 08)

This text panel provides additional information for Yorvipath (palopegteriparatide injection, solution), including a help contact advising patients to seek advice from healthcare providers or to call the Ascendis Pharma Helpline. It lists the toll-free phone number and the manufacturer address in Denmark.*

FDA Label Image

Image (Yorvipath 09)

A troubleshooting guide panel for the Yorvipath (Palopegteriparatide) injection pen. It provides detailed answers to common user questions about pen flow testing, needle drops, injection completion, holding the pen in the skin, dose selector issues, and the red lock needle cover, offering step-by-step instructions for each scenario.*

FDA Label Image

Image (Yorvipath 10)

A drug facts panel titled 'Storing Your Pen' for Yorvipath (palopegteriparatide) injection, solution. It provides storage instructions including refrigeration between 2°C to 8°C before first use, storing at room temperature below 30°C after first use for 14 days, avoiding exposure to extreme temperatures, not freezing the pen, and keeping it away from heat and children. A usage tip advises taking the pen out of the refrigerator 20 minutes before the first use to allow the medicine to reach room temperature.*

FDA Label Image

Image (Yorvipath 11)

This text panel titled 'Caring For Your Pen' provides instructions for handling a medication pen, including keeping it dry, cleaning with a moist cloth, avoiding drops or knocks, not applying extra force, and not attempting self-repair. It advises contacting the Ascendis Pharma Helpline if the pen is damaged.*

FDA Label Image

Image (Yorvipath 12)

A text panel providing important instructions for using the YORVIPATH pen for subcutaneous injection. It emphasizes correct injection technique, dosage options (6, 9, or 12 mcg), injection sites, training recommendations, and safety precautions including storage and usage limits.*

FDA Label Image

Image (Yorvipath 13)

A text panel providing detailed instructions for proper use of the Yorvipath injection pen, including single-patient use, checking expiration dates, inspecting the pen and medicine quality, using new needles for each injection, injection site guidance, proper needle removal and disposal, and warnings against changing the injection angle or reusing the pen beyond 14 days.*

FDA Label Image

Image (Yorvipath 14)

This text panel titled 'Compatible Pen Needles' provides instructions for compatible Clickfine AutoProtect needles (31G x 5mm) with Yorvipath prefilled pens for doses of 6, 9, or 12 mcg. It includes detailed guidance on proper disposal of Yorvipath needles and pens, emphasizing the use of FDA-cleared sharps disposal containers and describing their required features for safe disposal. It references regulations and safety practices for managing sharps waste.*

FDA Label Image

Image (Yorvipath 15)

An instructional diagram labeled 'Parts Overview' showing the components of a Yorvipath injection pen for subcutaneous use. It identifies pen parts including pen cap, inspection window with medicine inside, pen label, push button, dose selector, dose window, needle cover, needle with blue sleeve, and foil. Symbols for droplet, dose amounts (6, 9 or 12 mcg), and end-of-dose are explained. It highlights the single-use safety needle and notes no medicine is inside the needle. Additional needed items shown are a sharps disposal container and an alcohol wipe.*

FDA Label Image

Image (Yorvipath 16)

Illustrated step-by-step instructions for preparing Yorvipath injection pen and needle. Steps include washing hands, checking expiration dates on pen and needle, inspecting the medicine through a pen window to ensure clarity, peeling off the needle foil, attaching the needle to the pen by screwing it on, and removing the needle cover without touching the blue sleeve to avoid locking the needle.*

FDA Label Image

Image (Yorvipath 17)

Instructional illustration for using a Yorvipath injection pen, showing steps to test pen flow before first use. It includes turning the dose selector, tapping the pen to remove air bubbles, and pressing the push button to confirm medicine flow, with accompanying labeled diagrams of the pen and user actions.*

FDA Label Image

Image (Yorvipath 18)

Yorvipath injection, solution for subcutaneous use, with a visible strength of 168 micrograms per 0.56 milliliters. The product is labeled by Ascendis Pharma, Endocrinology, Inc. The label shows the proprietary name, generic name Palopegteriparatide, and contains storage and handling instructions along with dosage presentation details.*

FDA Label Image

Image (Yorvipath 19)

An instructional panel titled 'Prepare Injection and Select Dose' for the Yorvipath injection. It includes three steps: selecting an injection site on the stomach (abdomen) or thighs, washing hands and cleaning the injection site with an alcohol wipe, and selecting the dose on the pen by turning the dose selector clockwise. Illustrations show the injection sites on a body, use of an alcohol wipe, and dose selection on the pen injector.*

FDA Label Image

Image (Yorvipath 20)

Instructional illustrations showing steps for injecting a dose with the Yorvipath subcutaneous injection pen. The steps demonstrate holding the pen to the injection site with a visible dose window, pushing the pen straight to hear a click, pressing and holding the push button for 5 seconds, and slowly removing the pen while a blue sleeve locks around the needle for safety.*

FDA Label Image

Image (Yorvipath 21)

An instructional diagram showing steps 13 and 14 for safely disposing of a used needle after injection and securing the pen cap on a medication pen. Step 13 instructs to unscrew and safely discard the needle without recapping. Step 14 shows clicking the pen cap firmly to protect the pen and the medication from light between injections.*

FDA Label Image

Image (Yorvipath 22)

Instructional diagram labeled 'Throw Away Used Pen' for Yorvipath (palopegteriparatide) injection. The text advises discarding the pen and extra needles 14 days after first use, even if medicine remains. A graphic shows a used pen being discarded into a sharps container, emphasizing proper disposal timing and safety.*

FDA Label Image

Image (Yorvipath 23)

An instruction label image for Yorvipath (palopegteriparatide) injection for subcutaneous use. It highlights dosing options for 15, 18, or 21 mcg doses only. The image includes text stating the pen contains 294 mcg/0.98 ml (300 mcg/mL) prefilled for these doses and shows a visual of the Yorvipath prefilled injection pen.*

FDA Label Image

Image (Yorvipath 24)

This text panel titled 'Additional information' provides contact details for the Ascendis Pharma Helpline, including a toll-free telephone number and the company's address in Denmark. It advises patients to ask their health care provider or nurse for advice or to contact the helpline for assistance.*

FDA Label Image

Image (Yorvipath 25)

A text panel titled 'Troubleshooting' provides detailed instructions for users of the Yorvipath injection pen. It addresses common issues such as testing pen flow, absence of drops on the needle tip after repeated attempts, confirming injection completion, reasons for holding the pen in the skin for 5 seconds, dose selector problems, and proper handling of the needle before injection. The guidance emphasizes correct use to ensure accurate dosing and safe disposal of needles.*

FDA Label Image

Image (Yorvipath 26)

Text panel titled 'Storing Your Pen' providing storage instructions for Yorvipath injection pens, including refrigeration requirements before first use, room temperature storage guidelines, warnings against freezing and exposure to heat, and safety advice to keep the pen out of reach of children.*

FDA Label Image

Image (Yorvipath 27)

A text panel titled 'Caring For Your Pen' providing instructions for handling a pen device. It advises to handle gently, keep dry, clean with a moist cloth, avoid dropping or knocking on hard surfaces, and not to apply extra force or attempt self-repair. It also suggests contacting Ascendis Pharma Helpline if the pen is damaged.*

FDA Label Image

Image (Yorvipath 28)

This text panel provides important usage instructions for the Yorvipath injection pen containing Palopegteriparatide. It emphasizes careful reading of instructions, contacting healthcare providers for assistance, proper injection sites, dosage options (15, 18, or 21 mcg), and safe handling precautions including keeping the pen out of reach of children and those unfamiliar with its use.*

FDA Label Image

Image (Yorvipath 29)

This text panel provides detailed instructions for proper use of the Yorvipath (palopegteriparatide) injection pen. It includes guidance on pen and needle use, injection site selection, needle disposal, expiration checks, inspection of the medicine, and safe handling to avoid contamination or injury. It emphasizes following healthcare provider directions and safe injection practices.*

FDA Label Image

Image (Yorvipath 30)

Text panel titled 'Compatible Pen Needles' and 'For Correct Disposal' providing instructions for the use and disposal of disposable pen needles with Yorvipath prefilled pens. It details needle compatibility, safety tips on sharps disposal containers, and guidance on community disposal regulations.*

FDA Label Image

Image (Yorvipath 31)

An instructional diagram titled 'Parts Overview' showing components of the Yorvipath injection pen. It illustrates the pen cap, inspection window with medicine inside, pen body, pen label, push button, dose selector, dose window, needle cover, needle tip, blue sleeve, and foil. Symbols represent different doses (15, 18, 21 mcg) and end-of-dose. The diagram also shows the single-use safety needle and lists additional needed items: sharps disposal container and alcohol wipe.*

FDA Label Image

Image (Yorvipath 32)

Instructional diagram titled 'Prepare Pen And Needle' showing step-by-step illustrated instructions for preparing a Yorvipath pen for subcutaneous injection. Steps include washing hands, removing pen cap and inspecting medicine, pulling off needle foil, attaching needle to pen, and removing needle cover, with warning notes about expiration, medicine appearance, and needle use.*

FDA Label Image

Image (Yorvipath 33)

Illustration showing instructions for testing the pen flow on a Yorvipath injection pen. Steps include turning the dose selector to the droplet symbol, tapping the inspection window to release air bubbles, and pressing the push button to observe medicine flow from the needle tip, with visual aids and notes to assist proper procedure.*

FDA Label Image

Image (Yorvipath 34)

Yorvipath injection, solution in a 1.4 mL vial, containing 420 micrograms of palopegteriparatide. The vial label shows Ascendis Pharma, Endocrinology, Inc. as the manufacturer and indicates subcutaneous administration.*

FDA Label Image

Image (Yorvipath 35)

Instructional diagram for preparing and selecting dose for a subcutaneous injection. It shows choosing an injection site on the stomach or thighs, washing hands and cleaning the injection site with an alcohol wipe, and selecting the prescribed dose by turning a dose selector on the injection device. Includes visuals of body injection sites, a hand with alcohol wipe, and a close-up of the pen dose selector.*

FDA Label Image

Image (Yorvipath 36)

An instructional diagram showing steps 9 through 12 for injecting a dose with the Yorvipath prefilled pen. The illustrations depict holding the pen with the blue sleeve against the skin, pushing the pen straight until a click is heard, pressing and holding the push button for 5 seconds, and slowly removing the pen to see the blue sleeve lock around the needle, indicating a complete dose delivery for subcutaneous injection.*

FDA Label Image

Image (Yorvipath 37)

Illustration showing step-by-step instructions for disposing of a used needle and protecting the pen cap after subcutaneous injection, including unscrewing and discarding the needle safely and clicking the pen cap onto the injection pen to protect medicine from light.*

FDA Label Image

Image (Yorvipath 38)

An instructional illustration panel titled 'Throw Away Used Pen' advises discarding the pen 14 days after first use following local regulations. It shows a labeled injection pen next to a trash container with an arrow indicating disposal. The text emphasizes discarding the pen and needles after 14 days to ensure full medication effectiveness.*

FDA Label Image

Image (Yorvipath 39)

An instructional diagram for Yorvipath (palopegteriparatide) injection solution showing a 420 mcg/1.4 mL prefilled pen device for subcutaneous use. The instructions emphasize dosing options of 24, 27, or 30 mcg and state that the content guides how to inject Yorvipath.*

FDA Label Image

Image (Yorvipath 40)

A text panel titled 'Additional information' providing guidance for patients to contact their healthcare provider or Ascendis Pharma Helpline for advice. It includes the Ascendis Pharma toll-free helpline phone number and the company address in Denmark, focusing on patient support and contact details.*

FDA Label Image

Image (Yorvipath 41)

This image shows a troubleshooting guide for Yorvipath (palopegteriparatide) injection, solution, subcutaneous pen. It provides instructions on testing pen flow, addressing no drops after testing, confirming injection completion, holding the pen in the skin post-injection, handling dose selector issues, and managing the red lock needle cover before injection.*

FDA Label Image

Image (Yorvipath 42)

A text panel titled 'Storing Your Pen' providing storage instructions for Yorvipath (palopegteriparatide) injection pens. It advises refrigeration before first use, room temperature storage after first use for up to 14 days, and warnings against freezing or exposing the pen to heat. It also emphasizes keeping Yorvipath out of children's reach and includes a tip to allow the pen to reach room temperature 20 minutes before injection.*

FDA Label Image

Image (Yorvipath 43)

This image shows a patient instruction panel titled 'Caring For Your Pen' for Yorvipath (palopegteriparatide) injection pen. It provides guidelines on handling, cleaning, avoiding damage, proper use, and repair instructions for the subcutaneous injection pen device.*

FDA Label Image

Image (Yorvipath 44)

A text panel titled "Important Information You Need To Know Before Using Your YORVIPATH Pen" providing instructions for use. It explains the correct injection method for Yorvipath pen, dosage options (24, 27, or 30 mcg), intended use for 14 days, and warns against misuse. It advises users to seek training and assistance if needed, and includes storage and safety information.*

FDA Label Image

Image (Yorvipath 45)

Instructional text panel for Yorvipath (palopegteriparatide) injection pen, providing guidelines on proper pen use. It includes directions on single-patient use, pen and needle inspection, needle disposal after 14 days, injection site rotation, handling instructions, and warnings about not changing the injection angle or bending needles to ensure safe administration.*

FDA Label Image

Image (Yorvipath 46)

A text panel titled 'Compatible Pen Needles' and 'For Correct Disposal' providing instructions for use and disposal of Yorvipath pen needles. It details compatible needle types, usage guidance, and disposal recommendations, including use of FDA-cleared sharps disposal containers or alternatives that meet specified safety criteria, plus a reference to the FDA's sharps disposal website.*

FDA Label Image

Image (Yorvipath 47)

An instructional diagram showing the parts overview of the Yorvipath (palopegteriparatide) injection pen. It labels components including the pen cap, inspection window, pen body, pen label, push button, dose selector, dose window, needle cover, needle, blue sleeve, and foil. It also highlights single-use safety needle usage and shows additional required items: a sharps disposal container and an alcohol wipe.*

FDA Label Image

Image (Yorvipath 48)

An instructional diagram titled 'Prepare Pen And Needle' showing five steps for preparing the Yorvipath injection pen and needle for subcutaneous use. Steps include washing hands, checking expiration date and medicine clarity via inspection windows, removing the pen cap and needle cap, attaching the needle to the pen, and removing the needle cover. Each step is illustrated with simple hand-and-pen diagrams highlighting the correct actions and key cautions.*

FDA Label Image

Image (Yorvipath 49)

An instructional diagram titled 'If New Pen, Test Pen Flow' showing steps to test flow for a new injection pen. It includes visuals and corresponding text for turning the dose selector, tapping to remove air bubbles, and pressing the push button to observe medicine flow. The images depict hand actions and pen details for subcutaneous injection use.*

FDA Label Image

Image (Yorvipath 50)

Yorvipath 168 mcg/0.56 mL injection solution for subcutaneous use, displayed in a glass vial with a grey rubber stopper and blue plastic cap. The label indicates the active ingredient Palopegteriparatide and the manufacturer is Ascendis Pharma, Endocrinology, Inc.*

FDA Label Image

Image (Yorvipath 51)

An instructional diagram detailing injection preparation and dose selection steps for a subcutaneous injection. It shows selecting injection sites on the stomach and thighs, washing hands and the injection site with an alcohol wipe, and adjusting the dose using a dial on the injection pen. The instructions emphasize avoiding scarred or red areas and not pressing the push button while selecting the dose.*

FDA Label Image

Image (Yorvipath 52)

An instructional diagram titled 'Inject Dose' with steps 9 to 12 for using an injection pen. It includes four labeled figures showing hand positions and actions such as holding the pen to the injection site, pushing the pen straight into the skin, pressing and holding the push button for 5 seconds, and slowly removing the pen, highlighting the blue sleeve's locking mechanism. The section emphasizes following the technique recommended by a healthcare provider.*

FDA Label Image

Image (Yorvipath 53)

An illustrated instructional diagram showing steps for safely disposing of a used needle and securing the pen cap on a subcutaneous injection device. The image depicts unscrewing the needle to discard it safely, then clicking the pen cap back onto the injection pen to protect the medicine from light and ensure safety.*

FDA Label Image

Image (Yorvipath 54)

An instructional illustration showing how to discard the Yorvipath injection pen. The image includes text advising to throw away the pen 14 days after first use and to discard any extra needles after 14 days, even if medicine remains. A graphic depicts the pen being placed into a sharps disposal container.*

FDA Label Image

Principal Display Panel (168 mcg/0.56 mL Pen Carton)

The image shows the flat, unfolded carton label for Yorvipath (palopegteriparatide) injection, 168 mcg/0.56 mL prefilled pens. The label indicates it is for subcutaneous use, single patient use only, and contains two prefilled pens per box. It includes usage instructions, storage information, and the Ascendis Pharma logo. A barcode and QR code with lot and expiration placeholders are visible as well.*

FDA Label Image

Principal Display Panel (294 mcg/0.98 mL Pen Carton)

This is a flat carton packaging label for Yorvipath 294 mcg/0.98 mL prefilled pens injection, containing palopegteriparatide for subcutaneous use. The package is labeled for 15 mcg, 18 mcg, or 21 mcg doses only, intended for a single patient. The label shows product branding with the Ascendis Pharma, Endocrinology, Inc. logo and includes storage instructions and safety information. Two images of the pens are depicted on the label.*

FDA Label Image

Principal Display Panel (420 mcg/1.4 mL Pen Carton)

Packaging label for Yorvipath (palopegteriparatide) 420 mcg/1.4 mL prefilled pens injection solution for subcutaneous use. The label indicates single patient use and provides storage instructions and usage precautions. Manufactured by Ascendis Pharma. The package contains 2 prefilled pens and needles for 14 days of use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.